{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:40:19Z","timestamp":1792428019132,"version":"4.5.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 BX004907"],"award-info":[{"award-number":["I01 BX004907"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR077194 , K08 AR069111"],"award-info":[{"award-number":["R01 AR077194 , K08 AR069111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Alopecia Areata (AA) is a common autoimmune disease characterized by non-scarring hair loss ranging from patches on the scalp to complete hair loss involving the entire body. Disease onset is hypothesized to follow the collapse of immune privilege of the hair follicle, which results in an increase in self-peptide\/MHC expression along the follicular epithelium. Hair loss is associated with infiltration of the hair follicle with putatively self-reactive T cells. This process is thought to skew the hair follicle microenvironment away from a typically homeostatic immune state towards one of active inflammation. This imbalance is mediated in part by the dominating presence of specific cytokines. While interferon-\u03b3 (IFN\u03b3) has been identified as the key player in AA pathogenesis, many other cytokines have also been shown to play pivotal roles. Mechanistic studies in animal models have highlighted the contribution of common gamma chain (\u03b3\n                    <jats:sub>c<\/jats:sub>\n                    ) cytokines such as IL-2, IL-7, and IL-15 in augmenting disease. IFN\u03b3 and \u03b3\n                    <jats:sub>c<\/jats:sub>\n                    cytokines signal through pathways involving receptor activation of Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). Based on these findings, JAK\/STAT pathways have been targeted for the purposes of therapeutic intervention in the clinical setting. Case reports and series have described use of small molecule JAK inhibitors leading to hair regrowth among AA patients. Furthermore, emerging clinical trial results show great promise and position JAK inhibitors as a treatment strategy for patients with severe or recalcitrant disease. Demonstrated efficacy from large-scale clinical trials of the JAK inhibitor baricitinib led to the first-in-disease FDA-approved treatment for AA in June of 2022. This review aims to highlight the JAK\/STAT signaling pathways of various cytokines involved in AA and how targeting those pathways may impact disease outcomes in both laboratory and clinical settings.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.955035","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T05:22:54Z","timestamp":1661836974000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":174,"title":["An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata"],"prefix":"10.3389","volume":"13","author":[{"given":"Maddison","family":"Lensing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S53985","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13520","article-title":"Quality of life in patients with alopecia areata: a hospital-based cross-sectional study","volume":"30","author":"Jankovic","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103061","DOI":"10.1016\/j.autrev.2022.103061","article-title":"The current state of knowledge of the immune ecosystem in alopecia areata","volume":"21","author":"Connell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.00807.x","article-title":"The hair follicle and immune privilege","volume":"8","author":"Paus","year":"2003","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701183","article-title":"Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack","volume":"128","author":"Ito","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1016\/B978-012689663-3\/50008-9","article-title":"CHAPTER 4 - cytokine signaling","volume-title":"The cytokine handbook","author":"Szente","year":"2003"},{"key":"B9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12382416","article-title":"Alopecia areata in aging C3H\/HeJ mice","volume":"102","author":"Sundberg","year":"1994","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00380.x","article-title":"Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts","volume":"111","author":"McElwee","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.176","article-title":"Transfer of alopecia areata to C3H\/HeJ mice using cultured lymph node-derived cells","volume":"135","author":"Wang","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5693572","DOI":"10.1155\/2020\/5693572","article-title":"Increased serum levels of IFN-gamma, IL-1beta, and IL-6 in patients with alopecia areata and nonsegmental vitiligo","volume":"2020","author":"Tomaszewska","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2340\/0001555576421423","article-title":"Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis)","volume":"76","author":"Teraki","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03523.x","article-title":"Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy","volume":"35","author":"Barahmani","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63151-3","article-title":"Collapse and restoration of MHC class-i-dependent immune privilege: exploiting the human hair follicle as a model","volume":"164","author":"Ito","year":"2004","journal-title":"Am J Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07377.x","article-title":"Interferon-gamma-deficient mice are resistant to the development of alopecia areata","volume":"155","author":"Freyschmidt-Paul","year":"2006","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23580.x","article-title":"Alopecia areata induced in C3H\/HeJ mice by interferon-gamma: evidence for loss of immune privilege","volume":"124","author":"Gilhar","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12518","DOI":"10.1038\/s41598-018-30997-3","article-title":"Induction of alopecia areata in C3H\/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma","volume":"8","author":"Shin","year":"2018","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203523","article-title":"The role of Stat5a and Stat5b in signaling by IL-2 family cytokines","volume":"19","author":"Lin","year":"2000","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: At the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e23154","DOI":"10.4161\/jkst.23154","article-title":"Interleukin-2 and STAT5 in regulatory T cell development and function","volume":"2","author":"Mahmud","year":"2013","journal-title":"JAKSTAT"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1539-1","article-title":"Lesional infiltration of mast cells, langerhans cells, T cells and local cytokine profiles in alopecia areata","volume":"307","author":"Zhang","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000486462","article-title":"Serum levels of interleukin-2 in patients with alopecia areata: Relationship with clinical type and duration of the disease","volume":"4","author":"Kasumagic-Halilovic","year":"2018","journal-title":"Skin Appendage Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23888.x","article-title":"Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H\/HeJ mice","volume":"125","author":"Freyschmidt-Paul","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160510267","article-title":"Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy","volume":"16","author":"Gao","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ph14050443","article-title":"Notch1 and IL-7 receptor signalling in early T-cell development and leukaemia","volume":"360","author":"Gonzalez-Garcia","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/ph14050443","article-title":"Deregulation of the interleukin-7 signaling pathway in lymphoid malignancies","volume":"14","author":"Lodewijckx","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd1866","article-title":"Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H\/HeJ mice","volume":"7","author":"Dai","year":"2021","journal-title":"Sci Adv"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.154.11.6031","article-title":"IFN-gamma-dependent IL-7 gene regulation in keratinocytes","volume":"154","author":"Ariizumi","year":"1995","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2006.05.001","article-title":"IL-15\/IL-15 receptor biology: a guided tour through an expanding universe","volume":"17","author":"Budagian","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1016\/B0-12-370879-6\/00484-1","article-title":"INTERLEUKINS | IL-15","volume-title":"Encyclopedia of respiratory medicine","author":"Hamid","year":"2006"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00429-6","article-title":"IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_80_18","article-title":"Serum interleukin-15 is a marker of alopecia areata severity","volume":"11","author":"Ebrahim","year":"2019","journal-title":"Int J Trichol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2021.03.006","article-title":"Evaluation of the level of serum interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata","volume":"96","author":"Askin","year":"2021","journal-title":"Bras Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.102103","article-title":"Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity","volume":"37","author":"El Aziz Ragab","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2019.82826","article-title":"Serum concentrations of selected proinflammatory cytokines in children with alopecia areata","volume":"36","author":"Tabara","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(98)00178-5","article-title":"Signal perception and transduction: the role of protein kinases","volume":"1449","author":"Schenk","year":"1999","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0040-7","article-title":"The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto","year":"2013","journal-title":"BioDrugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of n-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflammation Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of (( s)-2,2-Difluorocyclopropyl)((1 R,5 s)-3-(2-((1-methyl-1 h-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: Functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.02.007","article-title":"Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient","volume":"6","author":"Peterson","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13598","article-title":"Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring","volume":"56","author":"Vandiver","year":"2017","journal-title":"Int J Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.040","article-title":"Ruxolitinib for the treatment of severe alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02336-0","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata","author":"Mikhaylov","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B70","volume-title":"Aclaris therapeutics announces phase 2 clinical trial of ATI-501 oral in patients with alopecia areata met primary endpoint [press release]","year":"2019"},{"key":"B71","volume-title":"Pfizer announces positive top-line results from phase 2b\/3 trial of ritlecitinib in alopecia areata [press release]","year":"2021"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"B73","volume-title":"Concert pharmaceuticals reports positive topline resuslts for first CTP-543 phase 3 clinical trial in alopecia areata [press release]","year":"2022"},{"key":"B74","volume-title":"Concert pharmaceuticals reports positive topline results for second CTP-543 phase 3 clinical trial in alopecia areata [press release]","year":"2022"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical janus kinase inhibitors - a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145137","article-title":"The effect of JAK inhibitor on the survival, anagen re-entry, and hair follicle immune privilege restoration in human dermal papilla cells","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa243","article-title":"Tofacitinib for the treatment of ulcerative colitis, alopecia universalis, and atopic dermatitis: One drug, three diseases","volume":"27","author":"Honap","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1159\/000254503","article-title":"A new classification of alopecia areata","volume":"131","author":"Ikeda","year":"1965","journal-title":"Dermatologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000466704","article-title":"Bullying and quality of life in pediatric alopecia areata","volume":"3","author":"Christensen","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.041","article-title":"Tofacitinib for the treatment of alopecia areata in preadolescent children","volume":"80","author":"Craiglow","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14422","article-title":"Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study","volume":"38","author":"Jerjen","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B88","volume-title":"FDA Approves lilly and incyte's OLUMIANT\u00ae (baricitinib) as first and only systemic medicine for adults with severe alopecia areata [press release]","year":"2022"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.028","article-title":"Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution","volume":"83","author":"Thompson","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.030","article-title":"Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study","author":"de Lusignan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.02.027","article-title":"A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib","volume":"22","author":"Zhao","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13836","article-title":"Successful treatment of chronic severe alopecia areata with abrocitinib","volume":"63","author":"Bennett","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000780","article-title":"Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata","volume":"32","author":"Gambardella","year":"2021","journal-title":"Dermatitis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"B99","article-title":"Chapter two - covalent drugs in development for immune-mediated diseases","volume-title":"Annual reports in medicinal chemistry","author":"Sung","year":"2021"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32987-8","article-title":"JAK inhibitors and alopecia areata","volume":"393","author":"Gilhar","year":"2019","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"B103","volume-title":"Black box warning","author":"Delong","year":"2022"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.955035\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T09:37:33Z","timestamp":1676540253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.955035\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":104,"alternative-id":["10.3389\/fimmu.2022.955035"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.955035","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"955035"}}